

Remarks/Arguments

Claims 67-80 have been deleted. Claims 64-66 and 81-95 are currently pending.

The newly amended claims 64-65 are fully supported by the specification as filed and do not add new matter. Applicant believes that newly amended claims 64-65 as well as claim 66 are fully enabled, as Examiner previously admitted on page 2 of Paper No. 8 (Office Action mailed February 10, 2003).

Applicant believes new claim 81 is directed to a method of treatment using an antibody or fragment thereof to a defined polypeptide and/or nucleic acid sequence and is fully supported by the specification.

Respectfully submitted,



Karen L. Nicastro
Attorney/Agent for Applicant(s)
Registration No.: 35,968
Phone: (805) 447-7211
Date: December 11, 2003

Please send all future correspondence to:

US Patent Operations/KLN
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799